312 related articles for article (PubMed ID: 37190957)
21. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes.
Ashjian E; Clarke M; Pogue K
Am J Health Syst Pharm; 2023 Nov; 80(23):1708-1721. PubMed ID: 37632460
[TBL] [Abstract][Full Text] [Related]
22. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
23. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Agarwal R; Joseph A; Anker SD; Filippatos G; Rossing P; Ruilope LM; Pitt B; Kolkhof P; Scott C; Lawatscheck R; Wilson DJ; Bakris GL;
J Am Soc Nephrol; 2022 Jan; 33(1):225-237. PubMed ID: 34732509
[TBL] [Abstract][Full Text] [Related]
24. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
[TBL] [Abstract][Full Text] [Related]
25. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
26. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Li P; Cui Y; Xu X; Dong J; Liao L
Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Ding K; Li Z; Lu Y; Sun L
Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
[TBL] [Abstract][Full Text] [Related]
28. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
[TBL] [Abstract][Full Text] [Related]
29. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Goulooze SC; Snelder N; Seelmann A; Horvat-Broecker A; Brinker M; Joseph A; Garmann D; Lippert J; Eissing T
Clin Pharmacokinet; 2022 Mar; 61(3):451-462. PubMed ID: 34786651
[TBL] [Abstract][Full Text] [Related]
30. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A;
Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027
[TBL] [Abstract][Full Text] [Related]
31. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
32. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
Zheng Y; Ma S; Huang Q; Fang Y; Tan H; Chen Y; Li C
Kidney Blood Press Res; 2022; 47(4):219-228. PubMed ID: 35034019
[TBL] [Abstract][Full Text] [Related]
33. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
[TBL] [Abstract][Full Text] [Related]
34. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
[TBL] [Abstract][Full Text] [Related]
35. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
[TBL] [Abstract][Full Text] [Related]
36. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
[TBL] [Abstract][Full Text] [Related]
38. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
[TBL] [Abstract][Full Text] [Related]
39. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
[TBL] [Abstract][Full Text] [Related]
40. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
